- Home
- SBFG vs WHWK Comparison
SBFG vs WHWK Comparison
Compare SBFG & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | WHWK |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 187.4M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SBFG | WHWK |
|---|---|---|
| Price | $27.55 | $4.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 11.4K | ★ 355.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 27.33 | ★ 86.02 |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.16 | $1.76 |
| 52 Week High | $28.38 | $5.50 |
Technical Indicators
Market Signals| Indicator | SBFG | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 60.66 |
| Support Level | $20.94 | $3.79 |
| Resistance Level | $28.38 | $5.21 |
| Average True Range (ATR) | 0.79 | 0.28 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 65.76 | 77.27 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.